# Progress Note 03 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Higuchi Ichiyō (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI029-SYN
- Date: 2026-05-01
- Fictional facility: St. Posthumous Health Center
- Fictional author: Aiko Lindgren-Tanaka, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Two-week review on tuberculosis treatment. **S**

## History of present illness

Ms. Higuchi returns two weeks into treatment. She has taken all fourteen doses on daily video calls with the public health center nurse. The evening fevers stopped about ten days in, the night sweats are lighter, and the cough is less frequent and dry. She had mild nausea after the morning doses in the first week, which went once she moved them to bedtime with a small snack. Her urine and tears are orange, as expected. She has no yellowing, dark urine, abdominal pain, rash, numbness, or change in vision or colors. The liquid culture from her first sputum specimen grew Mycobacterium tuberculosis complex after twelve days. She is eating three meals and two snacks a day with the supplement drinks. The public funding was approved. She has begun to write again for about an hour each morning. **S**

| Element | Detail |
|---|---|
| Treatment | Fourteen of fourteen doses observed by video |
| Symptoms | No fever for four days; lighter night sweats; less cough |
| Side effects | Mild nausea in the first week, gone with bedtime dosing; orange urine and tears |
| Culture | Mycobacterium tuberculosis complex grown from the first specimen |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Respiratory | Positive | Occasional dry cough; no blood; less breathless |
| Constitutional | Positive | Lighter night sweats; no fever for four days; appetite better |
| Gastrointestinal | Negative | No nausea now; no vomiting, abdominal pain or jaundice |
| Eyes | Negative | No blurred vision or change in colors |
| Neurological | Negative | No numbness or tingling |

5 systems reviewed. **S**

## Current medications

- Isoniazid 100 mg tablets, two tablets (200 mg) daily **S**
- Rifampin (rifampicin) 150 mg capsules, three capsules (450 mg) daily **S**
- Pyrazinamide 500 mg tablets, two tablets (1000 mg) daily **S**
- Ethambutol 100 mg tablets, six tablets (600 mg) daily **S**
- Vitamin B6 (pyridoxine) 50 mg tablet, one tablet daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 100/62 mmHg; pulse 90 bpm; respirations 18/min; temperature 37.1 °C; oxygen saturation 97% on room air; weight 39.2 kg; BMI 17.9 kg/m². All vital signs are synthetic.

ALT: 22 U/L; AST: 24 U/L; Total bilirubin: 0.6 mg/dL; Visual acuity, right eye (ETDRS letters): 85; Visual acuity, left eye (ETDRS letters): 84. All results are synthetic.

## Change since baseline

- ALT: 12 U/L at baseline, 22 U/L at this visit **S**
- AST: 19 U/L at baseline, 24 U/L at this visit **S**
- Total bilirubin: 0.4 mg/dL at baseline, 0.6 mg/dL at this visit **S**
- Visual acuity, right eye (ETDRS letters): 85 at baseline, 85 at this visit **S**
- Visual acuity, left eye (ETDRS letters): 85 at baseline, 84 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Less tired; weight 39.2 kg, up 0.7 kg; temperature 37.1 °C, pulse 90 |
| Eyes | No icterus. Visual acuity 85 letters on the right and 84 on the left; Ishihara plates read correctly with each eye |
| Respiratory | A few fine crackles over the right upper zone, fewer than at diagnosis |
| Abdomen | Soft and non-tender; liver not enlarged |
| Neurological | Normal sensation and reflexes in the feet |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Pulmonary tuberculosis, intensive phase** (A15.0). Culture-confirmed, with a clear clinical response and full adherence. ALT 22, AST 24 and bilirubin 0.6 at two weeks, all normal. Vision unchanged on ethambutol. Susceptibility testing is under way on the isolate. With smear-negative disease, two weeks of effective treatment and improvement, the public health center agrees she is no longer considered infectious and may end the home precautions. **S**
   - Continue the four drugs and pyridoxine daily by video-observed therapy, at bedtime.
   - Stop ethambutol by phone once the isolate is shown to be susceptible to isoniazid and rifampin.
   - Sputum specimen today for smear and culture; another at two months.
   - Monthly liver tests in the intensive phase; call the same day for hepatitis symptoms or any change in vision.
2. **Moderate protein-calorie malnutrition, improving** (E44.0). Weight 39.2 kg, up 0.7 kg. **S**
   - Continue the meal plan and supplement drinks.
3. **Low income** (Z59.6). Public funding approved for her tuberculosis care. **S**
   - Social worker to help with the remaining clinic charges.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Symptom review: cough, sputum, fever, night sweats | At least monthly during treatment | Completed today | No fever for four days; lighter night sweats; occasional dry cough |
| Self-management | Weight and nutrition | Every visit; dose review if weight changes by more than about 5 kg | Completed today | 39.2 kg, up 0.7 kg; doses unchanged |
| Medication safety | Hepatitis symptom review (nausea, vomiting, abdominal pain, jaundice, dark urine) | Every visit and every observed dose | Completed today | Mild nausea in the first week only; no jaundice, dark urine or pain |
| Laboratory | Liver tests (ALT, AST, bilirubin) | Baseline; at two weeks and monthly in the intensive phase because of low weight and albumin; then for symptoms | Completed today | ALT 22, AST 24 U/L, bilirubin 0.6 mg/dL, all normal |
| Imaging | Visual acuity and color vision | Baseline and monthly while on ethambutol | Completed today | 85 letters on the right and 84 on the left; color vision normal |
| Laboratory | Sputum smear and culture | At diagnosis, at two weeks, and at the end of the intensive phase (two months) | Completed today | Liquid culture of the first specimen grew Mycobacterium tuberculosis complex at twelve days; two-week specimen sent today |
| Laboratory | Drug susceptibility testing of the first isolate | Once, on the first positive culture | Ordered | Set up on the isolate; result expected in about three weeks |
| Medication safety | Doses observed and missed (video-observed therapy) | Every visit | Completed today | Fourteen of fourteen doses observed |
| Medication safety | Peripheral neuropathy check, with pyridoxine | Every visit | Completed today | No neuropathy; pyridoxine 50 mg daily |
| Medication safety | Rifampin drug-interaction review, including hormonal contraception | With every new medicine | Completed today | No new medicines |
| Self-management | Home precautions and the criteria for release | Until two weeks of treatment with clinical improvement, for smear-negative disease | Completed today | Released from home precautions today with the public health center's agreement |
| Referral | Contact investigation (household and close contacts) | Led by the public health center, from diagnosis | Referred | Under way with the public health center; results not part of her record |
| Referral | Public funding and other help with costs | At diagnosis and as needed | Completed today | Public funding approved |
| Survey | Depression screen (PHQ-9) | At diagnosis, at two months, and at the end of treatment | Up to date | PHQ-9 8 at intake; next at two months |

## Goal progress

- Complete 182 daily doses within about six and a half months by video-observed therapy. In progress; target 2026-10-20. **S**
- Sputum culture negative at two months. In progress; target 2026-10-20. **S**
- Weight at least 44 kg (BMI about 20) by the end of treatment. In progress; target 2026-10-20. **S**
- Keep writing on a paced schedule without losing income during treatment. In progress; target 2026-10-20. **S**
- No drug-induced liver injury or loss of vision during treatment. In progress; target 2026-10-20. **S**

## Guideline basis

- Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis (2016), American Thoracic Society, Centers for Disease Control and Prevention, and Infectious Diseases Society of America (Clinical Infectious Diseases 2016;63(7):e147-e195)
- WHO consolidated guidelines on tuberculosis: module 4: treatment: drug-susceptible tuberculosis treatment (2022), World Health Organization
- Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children (2017), American Thoracic Society, Infectious Diseases Society of America, and Centers for Disease Control and Prevention (Clinical Infectious Diseases)
- An official ATS statement: hepatotoxicity of antituberculosis therapy (2006), American Thoracic Society (American Journal of Respiratory and Critical Care Medicine)
- Guidelines for the investigation of contacts of persons with infectious tuberculosis: recommendations from the National Tuberculosis Controllers Association and CDC (2005), Centers for Disease Control and Prevention (MMWR Recommendations and Reports)
- 結核 (Tuberculosis): notification criteria under Article 12 of the Infectious Diseases Control Law (current), Ministry of Health, Labour and Welfare, Japan
- 結核医療費の公費負担 (Public funding of tuberculosis medical costs under Articles 37 and 37-2 of the Infectious Diseases Control Law) (current), Niigata Prefecture, Japan
- Consensus statement: Academy of Nutrition and Dietetics and American Society for Parenteral and Enteral Nutrition: characteristics recommended for the identification and documentation of adult malnutrition (undernutrition) (2012), Academy of Nutrition and Dietetics and American Society for Parenteral and Enteral Nutrition (JPEN)

## Follow-up

- Ethambutol stopped by phone when susceptibility results return. Monthly liver tests. End-of-intensive-phase review at eight weeks with the two-month sputum. Call the same day for hepatitis symptoms or any change in vision. **S**
- Next scheduled visit 2026-06-12: end of the eight-week intensive phase: susceptibility results, the two-month sputum culture, and the start of the continuation phase. **S**
